ACE2 and acute respiratory distress syndrome: In human trials, GSK2586881 has been found to reduce Ang II levels and increase Ang(1-7) levels; although failed to improve the physiological and clinical indicators of ARDS in patients, it did not promote adverse injury as a whole.25 This study proved that 44 patients with ARDS were well tolerated after using rhACE2, and they are most likely to represent the first clinical application in the field of ARDS.26 The potential of protecting lung injury by supplementing ACE2 has led to a clinical proof-of-concept study using rhACE2 in patients with COVID-19.